Antibody Industry Trends

Antibody gene transfer is advancing the landscape of therapeutic antibody development. Amid the logistical and economic constraints of recombinant monoclonal antibody (mAb) production, nucleic acid-encoded antibody platforms (delivering DNA, mRNA, or viral vectors encoding antibody genes) are emergi

With the boom of artificial intelligence (AI), the landscape of antibody discovery and engineering is undergoing an exciting transformation. AI is increasingly embedded across all stages of the antibody development pipeline, driving rapid advances in computational biology and enabling the emergence of specialized AI-powered platforms for antibody design, discovery, and optimization.

Biointron’s Q3 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September. This quarter, 2 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: both from China.

For decades, the blood-brain barrier (BBB) was believed to be a shield that restricted efficient penetration of large antibody therapeutics from the central nervous system. This perception limited efforts to treat neurological diseases with biologics.

Monoclonal antibody (mAb) cost and accessibility challenges have fueled the development of biosimilars: biologic products designed to be copies of the reference mAb, but are often slightly different in pharmacodynamic and pharmacokinetic properties because of changes in glycosylation.

Antibody conjugates extend the therapeutic potential of monoclonal antibodies by linking them to diverse payloads, broadening their mechanisms of action.

Recent advances in high-throughput technologies are reshaping the antibody discovery landscape, with platforms now capable of rapidly producing highly specific, naturally paired antibodies. As reviewed by Wang et al. (2025), antibody library display systems (phage, yeast, bacterial, and ribosome dis

Antibody–drug conjugates (ADCs) merge the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. Central to this system is the linker: a molecular bridge that dictates not only the stability of the ADC in circulation but also the precision and kinetics of payload r

Multispecific antibodies are increasingly being explored in the pharmaceutical industry for unmet patient needs, reshaping therapeutic possibilities by targeting multiple disease pathways simultaneously.

This August, we have seen several exciting antibody drug development announcements across Breakthrough Therapy, Fast Track, and Orphan Drug designations from regulatory agencies.Breakthrough Therapy Designations (BTDs): ADCs Drive Oncology InnovationOn August 27, Genmab announced BTD for

The last decade has seen a dramatic shift in the strategic development of antibody-based therapeutics for infectious diseases. Monoclonal antibodies (mAbs) have emerged as central agents in pandemic preparedness and the treatment of resistant infections. Driven by technological advances in sequencin

Sjögren’s disease (SjD) is a chronic, systemic autoimmune disorder characterized by lymphocytic infiltration of exocrine glands, most commonly the salivary and lacrimal glands, often accompanied by multi-organ extra-glandular involvement. Despite its substantial morbidity, therapeutic intervention